The chronic myeloid leukemia market reached a value of USD 5.7 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 9.2 Billion by 2035, exhibiting a growth rate (CAGR) of 4.47% during 2025-2035.
Chronic myeloid leukemia (CML) is an infrequent yet lethal hematologic malignancy. The global market for CML therapeutics is projected to grow rapidly in the coming years as a result of the increasing incidence, advanced treatment options, novel patient-centric technologies, and innovations occurring within the industry. Patients, doctors, and even investors stand to benefit and become more informed by tracking these market shifts.
Rising Incidence and Patient Awareness
More individuals are being diagnosed with chronic myeloid cancer (CML) in recent times. This increase has been attributed to heightened awareness, increased screening campaigns coupled with more advanced technology for diagnosing cancer. Increased surveillance by the American Cancer Society showed rising prevalence not only in the United States but also globally which positively impacts availability of effective therapies . Along with wider symptom knowledge healthcare access rises earlier among patients leading to expanded demand for early stage care bolstering affordable patient centered therapies.
Market Growth Driven by Targeted Medicines
The cornerstone of CML treatment continues to be targeted therapies. These include TKIs imatinib, dasatinib, nilotinib, and newer ones like asciminib and bosutinib. The survival benefits provided by TKIs are remarkable; with more than 90% patient survival over five years. The CML market was estimated at approximately USD 5-9 billion in 2024-25, with a steady annual growth projection of 4-7%. Increased diagnoses along with ongoing improvements in treatment are driving TKI sales.
Redefining Treatment Through New Technology
Managing CML is affected by new technologies. Asciminib’s diversified approach to targeting CML makes it a recent advancement (brand: Scemblix). It is widely adopted because of its accelerated FDA approval and improved outcomes coupled with lower side effects. In comparative trials, Scemblix outperformed older TKIs in major molecular response with nearly 20% greater efficacy and less than half the discontinuations.
Request for a sample of this report: https://www.imarcgroup.com/chronic-myeloid-leukemia-market/requestsample
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country:
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the Chronic myeloid leukemia market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the Chronic myeloid leukemia market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the current Chronic myeloid leukemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Competitive Landscape with key players:
The competitive landscape of the Chronic myeloid leukemia market has been studied in the report with the detailed profiles of the key players operating in the market.
1. Bristol-Myers Squibb
2. Novartis
3. Pfizer
4. Takeda Pharmaceutical
5. Novartis
6. Kartos Therapeutics
7. Enliven Therapeutics
8. Sun Pharma Advanced Research Company
9. AOP Orphan Pharmaceuticals
Explore the Full Report with TOC: Chronic Myeloid Leukemia Drugs Market Epidemiology
Countries Covered
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
